APPOINTMENTS: Apellis, Araim, Ascendis, Chronos, Intrexon and Proteostasis

Chrono Therapeutics Inc., a private biotech company focused on ageing diseases, brain and nervous system disorders, has named Drs. Fraser Murray and Timothy Schulz-Utermoehl vice presidents of pre-clinical development. The pair join Chronos from Polleo Pharma, a UK biotech start-up company they co-founded, and will be responsible for three preclinical research programs recently acquired by Chronos from Shire PLC – these include a dopamine active transporter inhibitor program in multiple sclerosis fatigue and the company's orexin 1 antagonist program in addictive behaviors. Both Murray and Schulz-Utermoehl have previously held leadership roles at Shire plc, AstraZeneca PLC and Merck & Co. Inc. Prior to founding Polleo Pharma Murray was senior director and head of discovery biology for Shire Speciality Pharmaceuticals; and Schulz-Utermoehl was a director within the exploratory projects department for Shire.

Apellis Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds for the treatment of autoimmune...